Page last updated: 2024-08-21

treosulfan and Hematologic Diseases

treosulfan has been researched along with Hematologic Diseases in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aljurf, MD; Arat, M; Bader, P; Boelens, JJ; Duarte, R; Faraci, M; Lawitschka, A; Peters, C; Socie, G; Tichelli, A; Veys, P; Wachowiak, J; Yaniv, I1
Bamberg, M; Dichgans, J; Duffner, F; Hermisson, M; Kortmann, RD; Küker, WM; Weller, M; Wick, W1
Baumgart, J; Becker, M; Fichtner, I1
Corrie, PG; Cree, IA; Haass, N; Hengge, U; Kuwert, C; Neuber, K; Pföhler, C; Reinhold, U; Tilgen, W; Ugurel, S; Zutt, M1
Blau, IW; Blau, O; Göldner, H; Hopfenmüller, W; Knauf, W; Leschinger, N; Schmidt-Hieber, M; Thiel, E1

Trials

2 trial(s) available for treosulfan and Hematologic Diseases

ArticleYear
Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study.
    Journal of neuro-oncology, 2002, Volume: 59, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Glioblastoma; Hematologic Diseases; Humans; Male; Middle Aged; Neoadjuvant Therapy; Venous Thrombosis

2002
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
    Anti-cancer drugs, 2003, Volume: 14, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Pilot Projects; Survival Analysis; Uveal Neoplasms

2003

Other Studies

3 other study(ies) available for treosulfan and Hematologic Diseases

ArticleYear
Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.
    Bone marrow transplantation, 2015, Volume: 50, Issue:4

    Topics: Adolescent; Allografts; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Databases, Factual; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Quality of Health Care; Quality of Life; Retrospective Studies; Transplantation Conditioning; Vidarabine

2015
Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:6

    Topics: Animals; Antineoplastic Agents, Alkylating; Body Weight; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Hematologic Diseases; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Heterologous

2003
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Annals of hematology, 2007, Volume: 86, Issue:8

    Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007